# The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

> **NCT00401310** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 150 (actual)

## Conditions studied

- Middle Cerebral Artery Stroke

## Interventions

- **DRUG:** Comparator: Placebo
- **DRUG:** Comparator: MK0724

## Key facts

- **NCT ID:** NCT00401310
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 150 (ACTUAL)
- **Why stopped:** Termination date was 20-Oct-2008. Subjects were monitored during the post treatment 90 day follow-up period (per protocol) resulting in LPLV 19-Jan-2009.
- **Last updated:** 2015-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401310, "The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00401310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*